Thursday 27 September 2018 – 07:00 [PDT] 10:00 [EDT] 15:00 [BST]
Not your time zone? Find conversion here
Colorectal cancer (CRC) is the second most common form of cancer and cause-related deaths regardless of gender in the US and Europe. If CRC is detected and treated early, as a localized disease, the 5-year survival rate in the US is 90%; this plummets to only 12% for patients diagnosed with metastatic spread to distant organs. With recent advances in high-throughput molecular technologies and machine learning, there is renewed excitement surrounding early detection of CRC. Here, we discuss first-hand lessons learned about the appropriate application of these advanced technologies in assay development.
What will you learn?
- Biomarker selection strategies for budget friendly method development
- Intro to xMAP®
- Machine learning validation versus test data sets
- Biospecimen selection, handling and storage
Who may this interest?
- IVD Scientist
- Research Scientist
- Lab Managers
- Data Scientists
- New Product Developers
- Business Development
- IVD Marketers
Jason L. Liggett, PhD
EDP Biotech Corp.
Over the last 15 years Jason has gained experience in laboratory science including: clinical, research and development work. After working as Clinical Laboratory Technologist in the University of Tennessee Medical Center’s (TN, USA) core lab, he returned to research at UT’s Comparative and Experimental Medicine department and continued to study NSAID and phytochemical molecular pathways in human colorectal cancer. Since joining EDP Biotech (TN, USA), a small start-up company, in 2014 he has worked with partners to develop a serum based test for the early detection of colorectal cancer.